Search
Interleukin-10
go.drugbank.com/bio_entities/BE0002484TargetHumansMechanistically, IL10 binds to its heterotetrameric receptor comprising IL10RA and IL10RB leading to JAK1 and STAT2-mediated phosphorylation of STAT3 (PubMed:16982608). … In turn, STAT3 translocates to the nucleus where it drives expression of anti-inflammatory mediators (PubMed:18025162).
Polypeptides: Interleukin-10Synonyms: IL-10Aquaporin-10
go.drugbank.com/bio_entities/BE0018706TransporterHumansCould also be permeable to urea (PubMed:12084581). Among aquaglyceroporins, it exhibits a unique pH-gated glycerol transport activity, being more active at acidic pH.
Polypeptides: Aquaporin-10Synonyms: AQP-10, Aquaglyceroporin-10Calcium cation
go.drugbank.com/drugs/DB14577InvestigationalMixtures: POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 100 ML (PVC TORBA) SETLI, POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 100 ML (PVC TORBA) SETSİZInfluenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14407ApprovedInvestigationalVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Mixtures: VAXİGRİP 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 10 ADET, FluQuadri Quadrivalent Influenza Vaccine, 0.25 mlStannous chloride
go.drugbank.com/drugs/DB11056ApprovedThese complexes localize primarily in bone (40-50%) and infracted myocardium (0.01-0.02%/g of tissue) allowing for imaging of areas of altered osteogenesis or necrotic heart tissue [FDA Label]. … Tin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700].
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Standard therapy involves cortisol replacement, but typically requires supraphysiological glucocorticoid doses to lower both ACTH and adrenal androgens, resulting in chronic glucocorticoid overexposure … [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesRezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigationalRezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily. … It can only be administered intravenously but does not reach therapeutic concentrations in the central nervous system, eye and urine.
Synonyms: Echinocandin B, 1-((4R,5R)-4-hydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-l-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-l-allothreonine)-Helminth Infection
go.drugbank.com/conditions/DBCOND0082009Synonyms: Infection due to Class Cestoda and/or Class Trematoda and/or Phylum NemataMeningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
go.drugbank.com/drugs/DB10061ApprovedInvestigationalMeningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria _Neisseria meningitidis_ entering … the bloodstream and invading the blood-brain barrier to cause a variety of infections such as septicemia, meningitis, and pneumonia.